PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Kerr, Rachel Midgley
TI  - No Benefit to Adding BEV to Adjuvant CAP in CRC
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 11--11
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/11.1.short
4100  - http://mdc.sagepub.com/content/14/36/11.1.full
AB  - Although bevacizumab (BEV) has a role in the treatment of colorectal cancer (CRC), it has not been shown to increase the efficacy of doublet chemotherapy in the adjuvant setting. The final results from the Multicentre International Study of Capecitabine±Bevacizumab as Adjuvant Treatment of Colorectal Cancer [QUASAR 2; ISRCTN45133151], a randomized phase 3 trial that tested capecitabine with and without BEV in the adjuvant setting of stage II/III CRC are discussed in this article.